Shaping Success in Since 1991, TRAFALGAR ETHICS BOARD (TEB) has continued to expand its Client base of major Pharmaceutical Sponsors, Contract Research Organizations, Medical Device Manufacturers and Independent Investigators. TEB's reputation in bioethics continues to strengthen through Responsiveness, Focus on Customer Success, and Total Commitment to Study Participant Protection.
FDA Issues Final Guidance on IRB Continuing Review
6 Mar 12 FDA has issued the final guidance, "IRB Continuing Review after Clinical Investigation Approval." This guidance is intended to assist more > |
|
